logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical files provisional Australian patent application to protect peptide pain management program

The company has been advancing its non-addictive analgesic peptide program to replace highly addictive drugs such as morphine, fentanyl and oxycodone

PreveCeutical Medical Inc. - PreveCeutical Medical Inc files provisional application at the Australian Patent Office seeking protection for certain peptides analogues of dynorphin and their use in pain management
Peptides are also being studied as a therapeutic for treating brain cancer as well as athletes suffering from concussions

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) announced Wednesday that it has filed a provisional application at the Australian Patent Office with the aim of seeking protection for certain peptides analogues of dynorphin and their use in pain management.

"Building a library of intellectual properties and having these protected is our Company's strategy,” PreveCeutical CEO Stephen Van Deventer said in a statement.

“The provisional application filing for peptide IP will add tremendous value and building partnerships for commercialization of peptide-based therapies."

READ: PreveCeutical says cannabinoid Sol-gel formulations showed physical and chemical stability in study

PreveCeutical has been advancing its non-addictive analgesic peptide program to replace highly addictive drugs such as morphine, fentanyl and oxycodone. It is also being studied as a therapeutic product for treating athletes suffering from concussions. 

The company recently completed a preclinical study of a dynorphin pain peptide on rats that “demonstrated effectiveness in alleviating moderate inflammatory pain” after administration of a single dose. Researchers plan to test other shortlisted peptides in an in-vivo rat model.

Vancouver-based PreveCeutical is also seeing encouraging preliminary results from its research and development program which is expected to enable the company to generate key peptide therapeutics for use in the treatment of brain cancer. 

Preliminary screening in an aggressive brain cancer assay successfully identified four lead peptides that inhibit the activity of a target protein found in the progression in certain glioblastomas.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: PreveCeutical Medical Inc.

Price: 0.07 CAD

CSE:PREV
Market: CSE
Market Cap: $27.75 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

2 weeks, 4 days ago

2 min read